Deficiency of the sphingosine-1-phosphate (S1P) transporter Mfsd2b protects the heart against hypertension-induced cardiac remodeling by suppressing the L-type-Ca
Cardioprotection
Left-ventricular remodeling
Mfsd2b
Sphingosine-1-phosphate
Journal
Basic research in cardiology
ISSN: 1435-1803
Titre abrégé: Basic Res Cardiol
Pays: Germany
ID NLM: 0360342
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
received:
25
04
2024
accepted:
29
07
2024
revised:
26
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
7
8
2024
Statut:
aheadofprint
Résumé
The erythrocyte S1P transporter Mfsd2b is also expressed in the heart. We hypothesized that S1P transport by Mfsd2b is involved in cardiac function. Hypertension-induced cardiac remodeling was induced by 4-weeks Angiotensin II (AngII) administration and assessed by echocardiography. Ca
Identifiants
pubmed: 39110173
doi: 10.1007/s00395-024-01073-x
pii: 10.1007/s00395-024-01073-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Faculty of the Heinrich Heine University
ID : Clinician Scientist Track No. 2022-01
Organisme : Deutsche Forschungsgemeinschaft
ID : CRC 1116 Gerok
Organisme : Deutsche Forschungsgemeinschaft
ID : LE 940/7-1
Organisme : Deutsche Forschungsgemeinschaft
ID : PO 2247/2-1
Organisme : Deutsche Forschungsgemeinschaft
ID : TRR259
Organisme : Deutsche Forschungsgemeinschaft
ID : project B10
Informations de copyright
© 2024. The Author(s).
Références
Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, Knaus UG (1998) A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids. J Biol Chem 273:8137–8144. https://doi.org/10.1074/jbc.273.14.8137
doi: 10.1074/jbc.273.14.8137
pubmed: 9525917
Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128:388–400. https://doi.org/10.1161/CIRCULATIONAHA.113.001878
doi: 10.1161/CIRCULATIONAHA.113.001878
pubmed: 23877061
pmcid: 3801217
Cuspidi C, Sala C, Negri F, Mancia G, Morganti A (2012) Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 26:343–349. https://doi.org/10.1038/jhh.2011.104
doi: 10.1038/jhh.2011.104
pubmed: 22113443
Davare MA, Horne MC, Hell JW (2000) Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase. J Biol Chem 275:39710–39717. https://doi.org/10.1074/jbc.M005462200
doi: 10.1074/jbc.M005462200
pubmed: 10984483
Drazner MH (2011) The progression of hypertensive heart disease. Circulation 123:327–334. https://doi.org/10.1161/CIRCULATIONAHA.108.845792
doi: 10.1161/CIRCULATIONAHA.108.845792
pubmed: 21263005
Egom EE, Bae JS, Capel R, Richards M, Ke Y, Pharithi RB, Maher V, Kruzliak P, Lei M (2016) Effect of sphingosine-1-phosphate on L-type calcium current and Ca(2+) transient in rat ventricular myocytes. Mol Cell Biochem 419:83–92. https://doi.org/10.1007/s11010-016-2752-8
doi: 10.1007/s11010-016-2752-8
pubmed: 27372350
Eisner DA, Caldwell JL, Kistamás K, Trafford AW (2017) Calcium and excitation-contraction coupling in the heart. Circ Res 121:181–195. https://doi.org/10.1161/CIRCRESAHA.117.310230
doi: 10.1161/CIRCRESAHA.117.310230
pubmed: 28684623
pmcid: 5497788
Eisner DA, Caldwell JL, Trafford AW, Hutchings DC (2020) The control of diastolic calcium in the heart. Circ Res 126:395–412. https://doi.org/10.1161/CIRCRESAHA.119.315891
doi: 10.1161/CIRCRESAHA.119.315891
pubmed: 31999537
pmcid: 7004450
Erkens R, Kramer CM, Lückstädt W, Panknin C, Krause L, Weidenbach M, Dirzka J, Krenz T, Mergia E, Suvorava T, Kelm M, Cortese-Krott MM (2015) Left ventricular diastolic dysfunction in Nrf2 knock out mice is associated with cardiac hypertrophy, decreased expression of SERCA2a, and preserved endothelial function. Free Radic Biol Med 89:906–917. https://doi.org/10.1016/j.freeradbiomed.2015.10.409
doi: 10.1016/j.freeradbiomed.2015.10.409
pubmed: 26475037
Fang R, Zhang LL, Zhang LZ, Li W, Li M, Wen K (2017) Sphingosine 1-phosphate postconditioning protects against myocardial ischemia/reperfusion injury in rats via mitochondrial signaling and akt-gsk3β phosphorylation. Arch Med Res 48:147–155. https://doi.org/10.1016/j.arcmed.2017.03.013
doi: 10.1016/j.arcmed.2017.03.013
pubmed: 28625317
Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N (2012) The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 122:1416–1426. https://doi.org/10.1172/jci60746
doi: 10.1172/jci60746
pubmed: 22406534
pmcid: 3314466
Funk F, Kronenbitter A, Isic M, Flocke V, Gorressen S, Semmler D, Brinkmann M, Beck K, Steinhoff O, Srivastava T, Barbosa DM, Voigt K, Wang L, Bottermann K, Kotter S, Grandoch M, Flogel U, Kruger M, Schmitt JP (2022) Diabetes disturbs functional adaptation of the remote myocardium after ischemia/reperfusion. J Mol Cell Cardiol 173:47–60. https://doi.org/10.1016/j.yjmcc.2022.09.002
doi: 10.1016/j.yjmcc.2022.09.002
pubmed: 36150524
Gorski PA, Ceholski DK, Hajjar RJ (2015) Altered myocardial calcium cycling and energetics in heart failure—a rational approach for disease treatment. Cell Metab 21:183–194. https://doi.org/10.1016/j.cmet.2015.01.005
doi: 10.1016/j.cmet.2015.01.005
pubmed: 25651173
pmcid: 4338997
Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ, Edinger AL (2008) Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci USA 105:17402–17407. https://doi.org/10.1073/pnas.0802781105
doi: 10.1073/pnas.0802781105
pubmed: 18981422
pmcid: 2582319
Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, Li Z, Dodge-Kafka K, Jiang X, Bittman R, Hla T (2010) Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem 285:26825–26831. https://doi.org/10.1074/jbc.M110.147058
doi: 10.1074/jbc.M110.147058
pubmed: 20558741
pmcid: 2930681
Hall DD, Feekes JA, Arachchige Don AS, Shi M, Hamid J, Chen L, Strack S, Zamponi GW, Horne MC, Hell JW (2006) Binding of protein phosphatase 2A to the L-type calcium channel Cav1.2 next to Ser 1928, its main PKA site, is critical for Ser1928 dephosphorylation. Biochemistry 45:3448–3459. https://doi.org/10.1021/bi051593z
doi: 10.1021/bi051593z
pubmed: 16519540
Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. https://doi.org/10.1016/s0140-6736(14)60107-0
doi: 10.1016/s0140-6736(14)60107-0
pubmed: 24831770
pmcid: 4330973
Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358:1370–1380. https://doi.org/10.1056/NEJMra072139
doi: 10.1056/NEJMra072139
pubmed: 18367740
Jin Z-Q, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS (2007) A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res 76:41–50. https://doi.org/10.1016/j.cardiores.2007.05.029
doi: 10.1016/j.cardiores.2007.05.029
pubmed: 17610857
Józefczuk E, Nosalski R, Saju B, Crespo E, Szczepaniak P, Guzik TJ, Siedlinski M (2020) Cardiovascular effects of pharmacological targeting of sphingosine kinase 1. Hypertension 75:383–392. https://doi.org/10.1161/HYPERTENSIONAHA.119.13450
doi: 10.1161/HYPERTENSIONAHA.119.13450
pubmed: 31838904
Jujic A, Matthes F, Vanherle L, Petzka H, Orho-Melander M, Nilsson PM, Magnusson M, Meissner A (2021) Plasma S1P (sphingosine-1-phosphate) links to hypertension and biomarkers of inflammation and cardiovascular disease: findings from a translational investigation. Hypertension 78:195–209. https://doi.org/10.1161/HYPERTENSIONAHA.120.17379
doi: 10.1161/HYPERTENSIONAHA.120.17379
pubmed: 33993723
Juraszek B, Nalecz KA (2016) Protein phosphatase PP2A—a novel interacting partner of carnitine transporter OCTN2 (SLC22A5) in rat astrocytes. J Neurochem 139:537–551. https://doi.org/10.1111/jnc.13777
doi: 10.1111/jnc.13777
pubmed: 27537937
Ke Y, Lei M, Solaro RJ (2008) Regulation of cardiac excitation and contraction by p21 activated kinase-1. Prog Biophys Mol Biol 98:238–250. https://doi.org/10.1016/j.pbiomolbio.2009.01.007
doi: 10.1016/j.pbiomolbio.2009.01.007
pubmed: 19351515
Keul P, Sattler K, Levkau B (2007) HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev 12:301–306. https://doi.org/10.1007/s10741-007-9038-x
doi: 10.1007/s10741-007-9038-x
pubmed: 17554629
Keul P, van Borren MM, Ghanem A, Müller FU, Baartscheer A, Verkerk AO, Stümpel F, Schulte JS, Hamdani N, Linke WA, van Loenen P, Matus M, Schmitz W, Stypmann J, Tiemann K, Ravesloot JH, Alewijnse AE, Hermann S, Spijkers LJ, Hiller KH, Herr D, Heusch G, Schäfers M, Peters SL, Chun J, Levkau B (2016) Sphingosine-1-phosphate receptor 1 regulates cardiac function by modulating Ca
doi: 10.1161/jaha.116.003393
pubmed: 27207969
pmcid: 4889204
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412. https://doi.org/10.1371/journal.pbio.1000412
doi: 10.1371/journal.pbio.1000412
pubmed: 20613859
pmcid: 2893951
Kim SM, Roy SG, Chen B, Nguyen TM, McMonigle RJ, McCracken AN, Zhang Y, Kofuji S, Hou J, Selwan E, Finicle BT, Nguyen TT, Ravi A, Ramirez MU, Wiher T, Guenther GG, Kono M, Sasaki AT, Weisman LS, Potma EO, Tromberg BJ, Edwards RA, Hanessian S, Edinger AL (2016) Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways. J Clin Invest 126:4088–4102. https://doi.org/10.1172/JCI87148
doi: 10.1172/JCI87148
pubmed: 27669461
pmcid: 5096903
Kotter S, Gout L, Von Frieling-Salewsky M, Muller AE, Helling S, Marcus K, Dos Remedios C, Linke WA, Kruger M (2013) Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res 99:648–656. https://doi.org/10.1093/cvr/cvt144
doi: 10.1093/cvr/cvt144
pubmed: 23764881
Kronenbitter A, Funk F, Hackert K, Gorreßen S, Glaser D, Boknik P, Poschmann G, Stühler K, Isić M, Krüger M, Schmitt JP (2018) Impaired Ca
doi: 10.1016/j.yjmcc.2018.04.004
pubmed: 29674140
Kruger M, Kohl T, Linke WA (2006) Developmental changes in passive stiffness and myofilament Ca
doi: 10.1152/ajpheart.00114.2006
pubmed: 16679402
Lei M, Wang X, Ke Y, Solaro RJ (2015) Regulation of Ca(2+) transient by PP2A in normal and failing heart. Front Physiol 6:13. https://doi.org/10.3389/fphys.2015.00013
doi: 10.3389/fphys.2015.00013
pubmed: 25688213
pmcid: 4310266
Levkau B (2008) Sphingosine-1-phosphate in the regulation of vascular tone. Circ Res 103:231–233. https://doi.org/10.1161/CIRCRESAHA.108.181610
doi: 10.1161/CIRCRESAHA.108.181610
pubmed: 18669929
Loescher CM, Hobbach AJ, Linke WA (2022) Titin (TTN): from molecule to modifications, mechanics, and medical significance. Cardiovasc Res 118:2903–2918. https://doi.org/10.1093/cvr/cvab328
doi: 10.1093/cvr/cvab328
pubmed: 34662387
Lorell BH, Carabello BA (2000) Left ventricular hypertrophy. Circulation 102:470–479. https://doi.org/10.1161/01.CIR.102.4.470
doi: 10.1161/01.CIR.102.4.470
pubmed: 10908222
Means CK, Brown JH (2009) Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 82:193–200. https://doi.org/10.1093/cvr/cvp086
doi: 10.1093/cvr/cvp086
pubmed: 19282351
pmcid: 2721649
Meissner A, Miro F, Jiménez-Altayó F, Jurado A, Vila E, Planas AM (2017) Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension. Cardiovasc Res 113:123–133. https://doi.org/10.1093/cvr/cvw256
doi: 10.1093/cvr/cvw256
pubmed: 28082452
Mendes AS, Blascke de Mello MM, Parente JM, Omoto ACM, Neto-Neves EM, Fazan R Jr, Tanus-Santos JE, Castro MM (2020) Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. Life Sci 244:117153. https://doi.org/10.1016/j.lfs.2019.117153
doi: 10.1016/j.lfs.2019.117153
pubmed: 31830479
Meyer zu Heringdorf D, Lass H, Kuchar I, Lipinski M, Alemany R, Rumenapp U, Jakobs KH (2001) Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled sphingosine-1-phosphate receptors. Eur J Pharmacol 414:145–154. https://doi.org/10.1016/s0014-2999(01)00789-0
doi: 10.1016/s0014-2999(01)00789-0
pubmed: 11239914
Meyer zu Heringdorf D, Liliom K, Schaefer M, Danneberg K, Jaggar JH, Tigyi G, Jakobs KH (2003) Photolysis of intracellular caged sphingosine-1-phosphate causes Ca
doi: 10.1016/s0014-5793(03)01219-5
pubmed: 14623109
Mills KT, Stefanescu A, He J (2020) The global epidemiology of hypertension. Nat Rev Nephrol 16:223–237. https://doi.org/10.1038/s41581-019-0244-2
doi: 10.1038/s41581-019-0244-2
pubmed: 32024986
pmcid: 7998524
(NCD-RisC) NRFC (2021) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398:957–980. https://doi.org/10.1016/s0140-6736(21)01330-1
doi: 10.1016/s0140-6736(21)01330-1
Polzin A, Dannenberg L, Benkhoff M, Barcik M, Helten C, Mourikis P, Ahlbrecht S, Wildeis L, Ziese J, Zikeli D, Metzen D, Hu H, Baensch L, Schröder NH, Keul P, Weske S, Wollnitzke P, Duse D, Saffak S, Cramer M, Bönner F, Müller T, Gräler MH, Zeus T, Kelm M, Levkau B (2023) Revealing concealed cardioprotection by platelet Mfsd2b-released S1P in human and murine myocardial infarction. Nat Commun 14:2404. https://doi.org/10.1038/s41467-023-38069-5
doi: 10.1038/s41467-023-38069-5
pubmed: 37100836
pmcid: 10133218
Polzin A, Dannenberg L, Benkhoff M, Barcik M, Keul P, Ayhan A, Weske S, Ahlbrecht S, Trojovsky K, Helten C, Haberkorn S, Flögel U, Zeus T, Müller T, Gräler MH, Kelm M, Levkau B (2023) Sphingosine-1-phosphate improves outcome of no-reflow acute myocardial infarction via sphingosine-1-phosphate receptor 1. ESC Heart Fail 10:334–341. https://doi.org/10.1002/ehf2.14176
doi: 10.1002/ehf2.14176
pubmed: 36217778
Polzin A, Piayda K, Keul P, Dannenberg L, Mohring A, Gräler M, Zeus T, Kelm M, Levkau B (2017) Plasma sphingosine-1-phosphate concentrations are associated with systolic heart failure in patients with ischemic heart disease. J Mol Cell Cardiol 110:35–37. https://doi.org/10.1016/j.yjmcc.2017.07.004
doi: 10.1016/j.yjmcc.2017.07.004
pubmed: 28709768
Polzin A, Dannenberg L, Benkhoff M, Barcik M, Keul P, Helten C, Zeus T, Kelm M, Levkau B (2022) S1P lyase inhibition starting after ischemia/reperfusion improves postischemic cardiac remodeling. JACC Basic Transl Sci 7:498–499. https://doi.org/10.1016/j.jacbts.2022.03.009
doi: 10.1016/j.jacbts.2022.03.009
pubmed: 35663625
pmcid: 9156442
Reventun P, Sánchez-Esteban S, Cook-Calvete A, Delgado-Marín M, Roza C, Jorquera-Ortega S, Hernandez I, Tesoro L, Botana L, Zamorano JL, Zaragoza C, Saura M (2023) Endothelial ILK induces cardioprotection by preventing coronary microvascular dysfunction and endothelial-to-mesenchymal transition. Basic Res Cardiol 118:28. https://doi.org/10.1007/s00395-023-00997-0
doi: 10.1007/s00395-023-00997-0
pubmed: 37452166
pmcid: 10348984
Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, Berrebi-Bertrand I (2001) EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 33:1589–1606. https://doi.org/10.1006/jmcc.2001.1433
doi: 10.1006/jmcc.2001.1433
pubmed: 11549339
Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B (2013) Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 5:105–121. https://doi.org/10.1002/emmm.201201283
doi: 10.1002/emmm.201201283
pubmed: 23180565
Santulli G, Xie W, Reiken SR, Marks AR (2015) Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci USA 112:11389–11394. https://doi.org/10.1073/pnas.1513047112
doi: 10.1073/pnas.1513047112
pubmed: 26217001
pmcid: 4568687
Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Gräler MH, Bröcker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B (2010) Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 105:821–832. https://doi.org/10.1007/s00395-010-0112-5
doi: 10.1007/s00395-010-0112-5
pubmed: 20652276
Sattler K, Levkau B (2009) Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 82:201–211. https://doi.org/10.1093/cvr/cvp070
doi: 10.1093/cvr/cvp070
pubmed: 19233866
Schmitt JP, Ahmad F, Lorenz K, Hein L, Schulz S, Asahi M, Maclennan DH, Seidman CE, Seidman JG, Lohse MJ (2009) Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca
doi: 10.1161/circulationaha.108.783506
pubmed: 19139388
Siedlinski M, Nosalski R, Szczepaniak P, Ludwig-Gałęzowska AH, Mikołajczyk T, Filip M, Osmenda G, Wilk G, Nowak M, Wołkow P, Guzik TJ (2017) Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. Sci Rep 7:44131. https://doi.org/10.1038/srep44131
doi: 10.1038/srep44131
pubmed: 28276483
pmcid: 5343497
Spiegel S, Milstien S (2003) Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem Soc Trans 31:1216–1219. https://doi.org/10.1042/bst0311216
doi: 10.1042/bst0311216
pubmed: 14641029
Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S (2010) Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 688:141–155. https://doi.org/10.1007/978-1-4419-6741-1_10
doi: 10.1007/978-1-4419-6741-1_10
pubmed: 20919652
pmcid: 2951632
Subbaiah KCV, Wu J, Tang WHW, Yao P (2022) FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling. JCI Insight. https://doi.org/10.1172/jci.insight.152783
doi: 10.1172/jci.insight.152783
pubmed: 35671117
pmcid: 9310534
Suthahar N, Meijers WC, Silljé HHW, de Boer RA (2017) From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr Heart Fail Rep 14:235–250. https://doi.org/10.1007/s11897-017-0343-y
doi: 10.1007/s11897-017-0343-y
pubmed: 28707261
pmcid: 5527069
Thomas N, Schroder NH, Nowak MK, Wollnitzke P, Ghaderi S, von Wnuck LK, Wille A, Deister-Jonas J, Vogt J, Graler MH, Dannenberg L, Buschmann T, Westhoff P, Polzin A, Kelm M, Keul P, Weske S, Levkau B (2023) Sphingosine-1-phosphate suppresses GLUT activity through PP2A and counteracts hyperglycemia in diabetic red blood cells. Nat Commun 14:8329. https://doi.org/10.1038/s41467-023-44109-x
doi: 10.1038/s41467-023-44109-x
pubmed: 38097610
pmcid: 10721873
Umbarkar P, Ejantkar S, Ruiz Ramirez SY, Toro Cora A, Zhang Q, Tousif S, Lal H (2023) Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis. Basic Res Cardiol 118:35. https://doi.org/10.1007/s00395-023-01005-1
doi: 10.1007/s00395-023-01005-1
pubmed: 37656238
Vessey DA, Kelley M, Li L, Huang Y, Zhou HZ, Zhu BQ, Karliner JS (2006) Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 12:Br318–Br324
pubmed: 17006394
Vessey DA, Li L, Honbo N, Karliner JS (2009) Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am J Physiol Heart Circ Physiol 297:H1429–H1435. https://doi.org/10.1152/ajpheart.00358.2009
doi: 10.1152/ajpheart.00358.2009
pubmed: 19648253
pmcid: 2770755
Vu TM, Ishizu AN, Foo JC, Toh XR, Zhang F, Whee DM, Torta F, Cazenave-Gassiot A, Matsumura T, Kim S, Toh SES, Suda T, Silver DL, Wenk MR, Nguyen LN (2017) Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets. Nature 550:524–528. https://doi.org/10.1038/nature24053
doi: 10.1038/nature24053
pubmed: 29045386
Xue Y, Jiang W, Ma Q, Wang X, Jia P, Li Q, Chen S, Song B, Wang Y, Zhang J, Liu J, Yang G, Lin Y, Liu J, Wei L, Dong C, Li H, Xie Z, Bai L, Ma A (2020) U-shaped association between plasma sphingosine-1-phosphate levels and mortality in patients with chronic systolic heart failure: a prospective cohort study. Lipids Health Dis 19:125. https://doi.org/10.1186/s12944-020-01262-2
doi: 10.1186/s12944-020-01262-2
pubmed: 32498720
pmcid: 7273664